2026 Healthcare Conference

Derek C. Archila is a managing director and senior Equity analyst at Wells Fargo covering Small & Midcap Biotechnology. He is an integral member of Wells Fargo’s #4 ranked biotech franchise and individually ranked as a “runner-up” in the Biotechnology Small & Midcap category in the 2023 & 2024 Institutional Investor poll. Previously, Derek was a part of the II-ranked franchise at Stifel and started his career on the sell-side at Leerink and Oppenheimer. Prior to the sell-side, Derek helped build out the Medtech business at GlobalData and spent 5 years in the Brigham & Women’s Hospital clinical hematology lab. Derek received a BS in Medical Lab Science and MBA from Northeastern University.

Mohit Bansal is a managing director and senior analyst at Wells Fargo Securities covering the Biotech and Pharmaceutical sectors. Mohit has more than 15 years of experience as a sell-side analyst covering the Biotech sector. In 2023, Mohit was ranked runner-up in Large-cap Biotech category by the Institutional Investor Poll. Prior to joining Wells Fargo, Mohit worked at Citi as a senior biotech analyst from 2015 to 2021. His career started his career in 2008 as an associate to II’s top-ranked biotech team. Mohit earned his MBA in finance from Nirma University (India) and his Bachelor in Engineering from the University of Rajasthan (India).

Stephen Baxter is an executive director and senior Equity analyst in the Equity Research Department at Wells Fargo Securities covering the Health Care Services sector. Stephen joined the firm from Wolfe Research, where he was a director and senior Equity analyst. In Q1 2019, Stephen was promoted to senior analyst at Wolfe Research and assigned coverage of labs, drug distributors and contract research. Prior to becoming a senior analyst, Stephen supported II-ranked Health Care Services franchises at Wolfe Research and BofA Securities. Stephen is a CFA charterholder and graduated from the University of Delaware with a BS in Finance.

Stan Berenshteyn is a senior analyst at Wells Fargo Securities covering the Digital Health sector. Previously, Stan was at Truist Securities (formerly SunTrust Robinson Humphrey) supporting coverage of Healthcare IT and CROs. He began his sell-side career at a boutique equity research firm as an analyst covering small-cap and micro-cap enterprise software. Stan’s extensive background also includes analyst positions in fixed income research, FP&A consulting and pension fund investment analysis. He graduated from the University of Maryland – Robert H. Smith School of Business with a BS in Finance. Stan is a CFA charterholder.

Larry Biegelsen is a managing director and the senior analyst covering the Medical Technology sector at Wells Fargo Securities. Larry has over 30 years of health care industry experience and has covered the medical device space for over 15 years. Prior to coming to Wall Street, he was a marketing director at Merck and a product manager at Pfizer Japan. Larry was the No. 2-ranked medical device analyst in the 2022 Institutional Investor poll of U.S.-based analysts. Larry received an MBA in finance from New York University and a BA in political science from Tulane University. He is also the author of the book, “U.S.-Japan Friction: Not Just A Laughing Matter,” published by Kodansha in 1992.

Ben Burnett, Ph.D., is an executive director and senior Equity analyst at Wells Fargo Securities covering the Small & Midcap Biotechnology sector. Ben previously worked at Stifel, where he was a key member of the Small & Midcap Biotechnology team that ranked runner-up in the 2024 Extel All-America equity research survey. Ben has covered Biotechnology stocks for the past nine years at Stifel and Leerink Partners. Ben earned a BS in engineering physics from Embry-Riddle Aeronautical University, a master’s degree in physics from Florida Institute of Technology, and a doctorate in biophysics from the Joan & Sanford I. Weill Medical College of Cornell University.

Eva is an executive director covering Small & Midcap Biotechnology. Prior to joining the firm, Eva earned her Ph.D. in Biophysics from Cornell University, a MSc in Physiology and Biophysics from the University of Montreal, and a BS in Microbiology from the Autonomous University of Barcelona.

Yanan Zhu is an executive director and senior analyst covering the Biotechnology sector with a focus on Genetic Medicines and Rare Diseases. Yanan has nine years of sell-side experience. He joined the firm in 2015 from BMO, where he started as an associate analyst following a broad range of biotech companies. Prior to his Wall Street career, Yanan was trained as a molecular immunologist and performed research on T and NK cells at the University of California San Francisco. His work experience also included a Global Marketing Internship at Novartis. Yanan holds a Ph.D. in Biochemistry and Immunology from the University of Colorado and an MBA from the Wharton School of the University of Pennsylvania.